AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
The clinical-stage biopharmaceutical company AC Immune (NASDAQ: ACIU) announced its participation in the Jefferies 2024 Global Healthcare Conference in New York, scheduled for June 5-6, 2024.
Company management will engage in a fireside chat on June 5 at 3:30 PM (ET), which can be accessed via webcast. Additionally, AC Immune will hold one-on-one meetings with investors. This involvement aims to highlight their precision medicine advancements for neurodegenerative diseases.
The webcast and an archived replay will be available on AC Immune’s website.
- AC Immune's participation in a prestigious event like the Jefferies Global Healthcare Conference increases visibility and credibility.
- The fireside chat and one-on-one meetings provide opportunities for investor engagement and potential new investments.
- Webcast availability ensures broader access to AC Immune’s strategic discussions and future plans, enhancing transparency.
- No new clinical data or financial performance details were shared in the announcement, limiting immediate impact on stock performance.
- The event is scheduled for June 2024, offering no short-term catalysts or immediate benefits for shareholders.
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person in New York on June 5-6, 2024.
The fireside chat will take place on Wednesday, June 5 at 3:30 PM (ET). A webcast of the fireside chat will be available at https://wsw.com/webcast/jeff302/aciu/1825568 as well as on the Events Page of AC Immune’s website. A replay will be archived in the same location.
Please contact your Jefferies representative to request a meeting with AC Immune’s management team at the conference.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | U.S. Investors Corey Davis, Ph.D. LifeSci Advisors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com |
| U.S. and International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 / +1 646 583 2369 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Attachment
FAQ
When will AC Immune present at the Jefferies 2024 Global Healthcare Conference?
What will AC Immune's management participate in during the Jefferies 2024 Global Healthcare Conference?
When is the AC Immune fireside chat scheduled?
Where can I access the webcast of AC Immune's fireside chat?
Will there be a replay of AC Immune's fireside chat at the Jefferies 2024 Global Healthcare Conference?
